Equities Analysts Offer Predictions for PRCT FY2028 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Equities researchers at Leerink Partnrs upped their FY2028 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a report released on Monday, October 28th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $0.12 per share for the year, up from their prior estimate of $0.10. The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.88) per share.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. The business had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. PROCEPT BioRobotics's quarterly revenue was up 66.4% on a year-over-year basis. During the same period last year, the company earned ($0.51) earnings per share.

A number of other research analysts also recently weighed in on PRCT. Piper Sandler restated an "overweight" rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. TD Cowen boosted their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Truist Financial reiterated a "buy" rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Wells Fargo & Company boosted their price target on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. Finally, Bank of America lifted their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, August 22nd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of "Buy" and a consensus price target of $88.40.

PROCEPT BioRobotics Stock Down 3.8 %

Shares of PROCEPT BioRobotics stock traded down $3.66 during trading hours on Wednesday, reaching $93.03. 2,036,163 shares of the company's stock were exchanged, compared to its average volume of 643,891. The company has a current ratio of 7.51, a quick ratio of 6.49 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average of $77.01 and a two-hundred day moving average of $67.73. The stock has a market cap of $4.83 billion, a P/E ratio of -47.09 and a beta of 1.03. PROCEPT BioRobotics has a fifty-two week low of $24.91 and a fifty-two week high of $99.34.

Insiders Place Their Bets

In related news, Director Antal Rohit Desai sold 13,305 shares of the company's stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the completion of the sale, the director now owns 317,518 shares of the company's stock, valued at $24,248,849.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 13,305 shares of the business's stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the completion of the transaction, the director now directly owns 317,518 shares in the company, valued at $24,248,849.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $82.51, for a total value of $2,062,750.00. Following the completion of the transaction, the chief financial officer now owns 96,096 shares in the company, valued at approximately $7,928,880.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 179,892 shares of company stock worth $13,946,415 in the last 90 days. Company insiders own 17.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PRCT. Vanguard Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 4,184,585 shares of the company's stock valued at $175,376,000 after acquiring an additional 109,694 shares during the last quarter. Diversified Trust Co boosted its stake in shares of PROCEPT BioRobotics by 25.4% during the first quarter. Diversified Trust Co now owns 13,442 shares of the company's stock valued at $664,000 after purchasing an additional 2,725 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of PROCEPT BioRobotics by 98.2% during the first quarter. Principal Financial Group Inc. now owns 20,983 shares of the company's stock valued at $1,037,000 after purchasing an additional 10,395 shares in the last quarter. SpiderRock Advisors LLC bought a new stake in shares of PROCEPT BioRobotics during the first quarter worth about $307,000. Finally, Essex Investment Management Co. LLC increased its stake in shares of PROCEPT BioRobotics by 0.6% in the first quarter. Essex Investment Management Co. LLC now owns 60,116 shares of the company's stock valued at $2,971,000 after buying an additional 336 shares during the period. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).